Nord/LB Reiterates “Buy” Rating for Fresenius Medical Care AG & Co. (FMS)

Fresenius Medical Care AG & Co. (NYSE:FMS)‘s stock had its “buy” rating reissued by investment analysts at Nord/LB in a research report issued on Tuesday.

Other analysts have also issued research reports about the stock. Royal Bank of Canada restated a “hold” rating and set a $44.00 price target on shares of Fresenius Medical Care AG & Co. in a research note on Wednesday, September 13th. SunTrust Banks set a $62.00 price target on shares of Fresenius Medical Care AG & Co. and gave the company a “buy” rating in a research note on Thursday, December 21st. DZ Bank restated a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research note on Monday, November 13th. Morgan Stanley lowered shares of Fresenius Medical Care AG & Co. from an “overweight” rating to an “equal weight” rating in a research note on Monday, December 11th. Finally, Zacks Investment Research lowered shares of Fresenius Medical Care AG & Co. from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. One analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $53.00.

Shares of Fresenius Medical Care AG & Co. (NYSE FMS) traded up $0.30 during mid-day trading on Tuesday, reaching $52.64. 83,100 shares of the company’s stock were exchanged, compared to its average volume of 101,350. The company has a market cap of $32,141.47, a price-to-earnings ratio of 23.61, a PEG ratio of 2.18 and a beta of 0.45. The company has a quick ratio of 0.98, a current ratio of 1.22 and a debt-to-equity ratio of 0.55. Fresenius Medical Care AG & Co. has a fifty-two week low of $39.46 and a fifty-two week high of $52.96.

A number of hedge funds have recently made changes to their positions in FMS. Harding Loevner LP boosted its holdings in Fresenius Medical Care AG & Co. by 4,271.1% during the 3rd quarter. Harding Loevner LP now owns 163,837,558 shares of the company’s stock worth $31,245,000 after acquiring an additional 160,089,385 shares during the last quarter. Cambiar Investors LLC boosted its holdings in Fresenius Medical Care AG & Co. by 3.8% during the 3rd quarter. Cambiar Investors LLC now owns 2,695,714 shares of the company’s stock worth $131,793,000 after acquiring an additional 99,234 shares during the last quarter. Royal Bank of Canada boosted its holdings in Fresenius Medical Care AG & Co. by 6.4% during the 2nd quarter. Royal Bank of Canada now owns 501,694 shares of the company’s stock worth $24,248,000 after acquiring an additional 30,119 shares during the last quarter. Parametric Portfolio Associates LLC boosted its holdings in Fresenius Medical Care AG & Co. by 8.9% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 431,183 shares of the company’s stock worth $21,081,000 after acquiring an additional 35,064 shares during the last quarter. Finally, Jarislowsky Fraser Ltd boosted its holdings in Fresenius Medical Care AG & Co. by 1.2% during the 3rd quarter. Jarislowsky Fraser Ltd now owns 294,871 shares of the company’s stock worth $14,416,000 after acquiring an additional 3,556 shares during the last quarter. Institutional investors and hedge funds own 3.02% of the company’s stock.

WARNING: This piece was posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://transcriptdaily.com/2018/01/04/nord-lb-reiterates-buy-rating-for-fresenius-medical-care-ag-co-fms.html.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply